FDA Section 361 Compliance Checklist for Allografts

Compliance under Section 361 of the Public Health Service (PHS) Act requires human cells, tissues, and cellular and tissue-based products (HCT/Ps) to be minimally manipulated, intended strictly for homologous use, manufactured without unapproved systemic agents, and distributed in accordance with 21 CFR Part 1271 regulations. For medical practice administrators and clinical leadership, executing an FDA Section 361 compliance checklist for biologic tissue allografts ensures that every tissue product procured, stored, and applied remains fully compliant with federal law while mitigating regulatory and financial exposure.

Understanding FDA Section 361 and 21 CFR Part 1271

Navigating the regulatory landscape for human cellular and tissue-based products requires a clear understanding of federal boundaries. The FDA regulates HCT/Ps under two primary frameworks: Section 361 and Section 351 of the Public Health Service (PHS) Act.

Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, or spread of communicable diseases. Products falling under Section 361 do not require pre-market approval, Biologics License Applications (BLA), or investigational new drug (IND) applications, provided they strictly fulfill specific regulatory criteria. Conversely, products categorized under Section 351 are treated as biological drugs or devices, requiring extensive clinical trial data and formal FDA pre-market licensure before commercial distribution.

The Four Criteria for Section 361 HCT/P Qualification

To qualify as a Section 361 HCT/P under 21 CFR 1271.10(a), a biologic tissue allograft must meet all four of the following regulatory thresholds:

1. Minimal Manipulation: Processing must not alter the relevant biological characteristics of the tissue. For structural tissues (such as amnion or cord tissue), processing cannot alter the tissue's utility for reconstruction, repair, or replacement.
2. Homologous Use: The tissue must perform the same basic function in the recipient as it performed in the donor. For example, structural allografts must be used for barrier, covering, or structural support applications.
3. No Unapproved Combinations: The tissue cannot be combined with another drug, device, or synthetic agent, with limited exceptions such as approved water, crystalloids, or sterilizing agents that do not alter the tissue's function.
4. Systemic Effect Boundaries: The tissue must not depend on the metabolic activity of living cells for its primary function, OR if it does have a systemic effect, it must be intended for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

Evaluating your supplier's product portfolio against these criteria is an essential step when adding structural tissue to your clinical catalog through reliable biologics channels.

FDA Section 361 Compliance Checklist for Biologic Tissue Allografts

To ensure operational safety, regulatory compliance, and audit readiness, practice managers should execute the following compliance checklist for every biologic tissue vendor and product lot entering the facility.

Vendor Evaluation & Tissue Establishment Registration

• [ ] FDA Tissue Registration Verification: Confirm that the manufacturer and primary distributor hold active FDA tissue establishment registrations (Form FDA 3356) visible in the FDA establishment database.
• [ ] State Licensing Compliance: Verify that the distributor and tissue bank hold required state-level biological tissue distributor licenses for your state (such as Texas tissue licenses).
• [ ] AATB Accreditation Verification: Determine whether the tissue processor is accredited by the American Association of Tissue Banks (AATB), ensuring adherence to voluntary standard operating procedures beyond baseline federal requirements.
• [ ] Quality Agreement Documentation: Maintain signed quality assurance agreements outlining vendor responsibility for tissue safety, recalls, and regulatory notices.

Donor Screening & Good Tissue Practice Documentation

• [ ] Summary of Records Availability: Confirm that each tissue lot is shipped with a clear Summary of Records verifying that donor eligibility screening and serological testing were completed under Current Good Tissue Practice (cGTP).
• [ ] Communicable Disease Testing Standards: Ensure testing includes standard infectious disease panels (HIV-1/2, Hepatitis B, Hepatitis C, Syphilis, HTLV, and relevant regional pathogens) performed by a CLIA-certified laboratory.
• [ ] Traceability Logging: Maintain a centralized inventory log tracking tissue lot numbers, expiration dates, donor identifiers, and internal tissue disposition.

Handling, Storage, and Cold-Chain Maintenance

• [ ] Temperature Log Records: Establish continuous, logged temperature monitoring for ultra-low freezers, liquid nitrogen storage, or ambient tissue storage units as specified by manufacturer instructions.
• [ ] Chain of Custody Verification: Document cold-chain verification upon delivery, ensuring temperature indicators or dry-ice packaging remained compliant during transit.
• [ ] Standard Operating Procedures (SOPs): Maintain updated administrative SOPs for tissue receipt, unpacking, inspection, quarantine of damaged goods, and emergency thaw/spill protocols.

Product Labeling and Claims Review

• [ ] Package Insert Review: Verify that product inserts clearly state structural function claims (e.g., wound covering, barrier function, tissue repair) and contain no unapproved clinical treatment claims.
• [ ] Marketing Material Audit: Review internal practice website copy and patient brochures to eliminate drug-like therapeutic claims (e.g., promising systemic cartilage regeneration or disease cures) that compromise 361 status.

For more detailed guidance on regulatory alignment and practice integration, practice leadership can reference our general regulatory insights on the about page.

Operational vs. Clinical Compliance: Dividing Responsibilities

Maintaining Section 361 compliance requires distinct operational workflows for administrative staff and clinical oversight from treating providers. Ambiguity between managerial duties and clinical decision-making increases compliance risks.

| Compliance Focus Area | Operational & Administrative Team | Treating Physicians & Clinicians | | :--- | :--- | :--- | | Vendor & Product Vetting | Audits supplier FDA establishment registration, tissue licenses, and cGTP documentation. | Reviews structural characteristics and suitability for intended clinical application. | | Inventory Management | Manages cold-chain logs, shelf-life rotation, lot tracking, and quarantine protocols. | Verifies package integrity, lot numbers, and expiration dates prior to application. | | Documentation & Charting | Retains vendor Summaries of Records and invoicing documentation for facility audits. | Charts tissue lot numbers, application site, and homologous clinical rationale in the EHR. | | Marketing & Patient Communications | Audits practice website, operational forms, and consent forms for compliant language. | Conducts clinical informed consent explaining structural benefits and limits without disease-cure claims. |

Operational & Administrative Responsibilities

Practice managers oversee procurement integrity and administrative tracking. They verify supplier licensure, track shipments, maintain freezer logs, and archive Summaries of Records. Operational leaders also ensure that practice marketing collateral uses non-drug, structural phrasing when describing biological services provided by regenerative medicine doctors.

Clinical & Provider Responsibilities

Licensed clinicians remain solely responsible for patient selection, determining homologous use appropriateness, conducting application procedures, and recording complete clinical documentation in patient electronic health records (EHR). Clinicians must confirm that the application site matches the homologous intended function of the tissue allograft.

What This Means for Your Practice: Concrete Action Steps

To solidify compliance across administrative and clinical workflows, practice managers should implement three practical steps:

1. Conduct an Immediate Vendor Document Audit: Contact your tissue suppliers today and request updated copies of their FDA Form 3356 registration, state licenses, and sample Summaries of Records for your active inventory.
2. Align Marketing and Clinical Language: Review patient intake forms, consent documents, and digital marketing materials. Remove terms that imply systemic biological drug action, reinforcing structural and homologous applications.
3. Formalize Tissue Receipt SOPs: Implement a standardized intake log capturing delivery temperature, lot tracking numbers, and staff initials for every incoming biological shipment.

Reviewing common administrative queries in our operational faq can help your team streamline these verification protocols.

Partnering for Compliant Biologics Procurement

Maintaining Section 361 compliance protects your practice reputation, operational continuity, and patient safety. Working with transparent biological distributors simplifies tissue tracking, vendor qualification, and quality record retention.

To discuss compliant biological tissue solutions, audit documentation, or practice integration support for your clinical facility, reach out to our team through our contact page.